#USA #New York #NYU Langone #Eye Care #Mohammad Dastjerdi

NYU Langone Eye Center Welcomes Dr. Mohammad Dastjerdi

In a significant advancement for the field of ophthalmology, NYU Grossman School of Medicine’s Department of Ophthalmology has announced the appointment of Dr. Mohammad H. Dastjerdi, a noted expert in corneal diseases. With over thirty years of experience, Dr. Dastjerdi is expected to play a pivotal role in the NYU Langone Eye Center as he establishes the region's first ocular surface stem cell transplant program.

Dr. Dastjerdi’s career is marked by his extensive training across two continents, equipping him with a wealth of knowledge in the medical and surgical treatment of complex corneal issues, including corneal transplantation, dry eye syndrome, and corneal neovascularization. Before joining NYU Langone Health, he served as an associate professor at Rutgers New Jersey Medical School, where he specialized in corneal and external diseases, cataract surgery, and anterior segment trauma.

Advancing Patient Care
Dr. Kathryn A. Colby, the chair of the Department of Ophthalmology at NYU Langone, expressed great optimism regarding Dr. Dastjerdi's vision for enhancing corneal care. She indicated that his collaborative and innovative approach aligns seamlessly with the center's commitment to providing cutting-edge patient care. This partnership is expected to improve treatment options for patients in the region who often encounter limited services for their corneal conditions.

A Comprehensive Approach to Eye Health
Dr. Dastjerdi's appointment signifies not only an enhancement of clinical services but also a focus on pioneering research. He earned his medical degree from Tehran University of Medical Sciences, and his journey through ophthalmology includes prestigious fellowships at the University of Michigan's Kellogg Eye Center and Harvard Medical School. His contributions to research on dry eye disease and corneal neovascularization have already gained considerable recognition, and he holds numerous patents related to therapeutic innovations in these areas.

“I am excited about the opportunity to integrate my expertise and resources at NYU Langone, where I can provide the level of care that my patients truly deserve,” commented Dr. Dastjerdi. He is particularly eager to see the impacts of his work, especially when patients regain their sight following treatment.

Future Aspirations
The establishment of the ocular surface stem cell transplant program is Dr. Dastjerdi’s primary focus. This procedure aims to address blinding conditions that affect the ocular surface, resulting from severe chemical injuries, infections, or autoimmune disorders. By collaborating with both the NYU Langone Eye Center and the NYU Langone Transplant Institute, he hopes to launch a comprehensive program capable of serving a diverse patient population across the tristate area and beyond.

In addition to developing this groundbreaking program, Dr. Dastjerdi will engage in ongoing clinical and surgical practices, focusing on corneal and external diseases, cataract cases, and trauma related to the anterior segment of the eye. He has also been recognized for his dedication to education, earning accolades from ophthalmology residents, and mentoring those learning cataract surgery over the years.

As he transitions into this new role, Dr. Dastjerdi remains an influential researcher and educator. He has contributed over 50 peer-reviewed articles to the field and frequently shares his insights and knowledge at international conferences.

About NYU Langone Health
NYU Langone Health is a leading integrated health system known for exceptional patient outcomes and top-ranked services by Vizient Inc. It operates multiple inpatient locations, cancer centers, and a vast network of outpatient facilities throughout New York and Florida, emphasizing quality care and patient safety. This commitment ensures that NYU Langone remains at the forefront of healthcare innovation.

Through Dr. Dastjerdi's arrival, NYU Langone Eye Center continues its commitment to advancing eye care and improving patients' lives, reinforcing its position as a leader in the field.